AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00206-07v1
51/7/2628    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cenizal, M. J.
Right arrow Articles by Hardy, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cenizal, M. J.
Right arrow Articles by Hardy, R. D.
Antimicrobial Agents and Chemotherapy, July 2007, p. 2628-2630, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00206-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Prospective Randomized Trial of Empiric Therapy with Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High Prevalence of Methicillin-Resistant Staphylococcus aureus{triangledown}

Mary Jo Cenizal,1 Daniel Skiest,1 Samuel Luber,1 Roger Bedimo,1,2 Pat Davis,1 Patrick Fox,1 Kathleen Delaney,1 and R. Doug Hardy1*

University of Texas Southwestern Medical Center,1 VA North Texas Health Care System, Dallas, Texas2

Received 12 February 2007/ Returned for modification 15 March 2007/ Accepted 4 May 2007

To evaluate empirical therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus, a randomized, prospective, open-label investigation was performed. The overall clinical failure rate was 9%, with all failures occurring in the trimethoprim-sulfamethoxazole group. However, there was no significant difference between the clinical failure rate of empirical trimethoprim-sulfamethoxazole therapy and that of doxycycline therapy.

* Corresponding author. Mailing address: Department of Internal Medicine and Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9063. Phone: (214) 648-3720. Fax: (214) 648-2961. E-mail: robert.hardy{at}utsouthwestern.edu

{triangledown} Published ahead of print on 14 May 2007.

Antimicrobial Agents and Chemotherapy, July 2007, p. 2628-2630, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00206-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.